Integrating Data: Daiichi, Takeda Join Lifestyle Project To Inform R&D

Industry Has Called For Initiatives

The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.

Study will use wearable device
Wearable devices will track lifecycles of 2,000 participants • Source: Shutterstock

Japanese research organization the Tohoku University Medical Megabank Organization (ToMMo), together with Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd. and Japanese digital healthcare firm MICIN, have launched a joint research project that will use lifestyle data from around 2,000 people to inform a detailed analysis of how personal habits are related to health and disease. 

The project - forming part of Japanese pharma's wider ongoing efforts to mover "beyond the pill" - will combine the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts

 
• By 

Several major Japanese firms, including Takeda, are planning layoffs at home and elsewhere as they make efforts to streamline their business and costs and cope with R&D and commercial challenges. 

Japan Results Roundup: Strong Mainstays, Currency Windfall Help Top Line

 
• By 

Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US. 

Win Some, Lose Some: Amid Otsuka-Jnana Deal, Delaware Court Favors Lupin For gJynarque

 
• By 

Otsuka Pharma’s acquisition of Jnana seems like a win for its pipeline, but the Japanese major faced a setback in a Delaware District Court where the judge’s opinion put challenger Lupin closer to a generic to its Jynarque (tolvaptan)

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.